Compare NX & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NX | AURA |
|---|---|---|
| Founded | 1927 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 819.4M | 797.5M |
| IPO Year | 2008 | 2021 |
| Metric | NX | AURA |
|---|---|---|
| Price | $19.85 | $7.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $28.00 | $20.00 |
| AVG Volume (30 Days) | 287.5K | ★ 766.9K |
| Earning Date | 06-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,837,641,000.00 | N/A |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $1.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.81 | N/A |
| 52 Week Low | $11.04 | $4.73 |
| 52 Week High | $22.90 | $9.54 |
| Indicator | NX | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 57.18 |
| Support Level | $15.52 | $6.49 |
| Resistance Level | $21.72 | $9.54 |
| Average True Range (ATR) | 0.73 | 0.48 |
| MACD | -0.20 | 0.00 |
| Stochastic Oscillator | 29.50 | 59.03 |
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.